Aclaris Therapeutics Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
91
- Stock Symbol
-
ACRS
- Investments
-
3
- Share Price
-
$1.19
- (As of Friday Closing)
Aclaris Therapeutics General Information
Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Contact Information
Corporate Office
- 701 Lee Road
- Suite 103
- Wayne, PA 19087
- United States
Aclaris Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.19 | $1.18 | $0.59 - $11.12 | $84.8M | 71.3M | 955K | -$1.09 |
Aclaris Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (30,733) | (28,364) | 802,964 | 693,032 |
| Revenue | 31,119 | 31,249 | 29,752 | 6,761 |
| EBITDA | (76,721) | (87,973) | (86,111) | (89,942) |
| Net Income | (77,262) | (88,481) | (86,908) | (90,865) |
| Total Assets | 174,065 | 197,405 | 254,596 | 251,211 |
| Total Debt | 426 | 684 | 693 |
Aclaris Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Aclaris Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Aclaris Therapeutics Comparisons
Industry
Financing
Details
000000
000000
Aclaris Therapeutics Competitors (21)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aquapharm (Scotland ) | Formerly VC-backed | Argyll and Bute, United Kingdom | 000.00 | 000000&0 | ||
| Azitra | Formerly VC-backed | Branford, CT | 00 | 000.00 | 00000000 | 000.00 |
| Novartis | Corporation | Basel, Switzerland | 00000 | 0000 | 000000000 | 0000 |
| Revance Therapeutics | Formerly VC-backed | Nashville, TN | 000 | 00000 | 00000000 | 00000 |
| Biogen | Formerly VC-backed | Cambridge, MA | 0000 | 000 | 000000&0 |
Aclaris Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aclaris Therapeutics Patents
Aclaris Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230286950-A1 | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds | Pending | 04-Feb-2022 | 0000000000 | 0 |
| CA-3208215-A1 | Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions | Pending | 18-Feb-2021 | 00000000000 | |
| AU-2022224689-A1 | Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions | Pending | 18-Feb-2021 | 00000000000 | |
| EP-4294809-A1 | Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions | Pending | 18-Feb-2021 | 00000000000 | |
| US-20220235025-A1 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | Active | 23-Nov-2020 | C07D401/14 | 0 |
Aclaris Therapeutics Executive Team (20)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Neal Walker Ph.D | Founder, President, Interim Chief Executive Officer & Chairman | ||
| Kevin Balthaser | Chief Financial Officer, Finance | ||
| James Loerop | Executive | ||
| Robert Doody Jr. | Senior Vice President, Investor Relations | ||
| Joseph Monahan Ph.D | Chief Scientific Officer |
Aclaris Therapeutics Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anand Mehra MD | Sofinnova Investments | Board Member, Member of the Compensation Committee, and Chair of the Research and Development Committee | 000 0000 |
| Andrew Powell JD | Aclaris Therapeutics | Board Member | 000 0000 |
| Andrew Schiff MD | Aisling Capital | Board Member, Member of the Compensation & Member of the Research and Development | 000 0000 |
| Bryan Reasons | Self | Board Member | 000 0000 |
| Christopher Molineaux | Self | Board Member | 000 0000 |
Aclaris Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Aclaris Therapeutics Investments & Acquisitions (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Allergan (Worldwide Rights to RHOFADE) | 15-Oct-2018 | 000000000 | 000.00 | Buildings and Property | 0000 0000 |
| Confluence Discovery Technologies | 03-Aug-2017 | 0000000000 | 000.00 | Drug Discovery | 0000 0000 |
| Vixen Pharmaceuticals | 24-Mar-2016 | Merger/Acquisition | 000.00 | Drug Discovery | 0000 0000 |
Aclaris Therapeutics Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Confluence Discovery Technologies | Drug Discovery | Saint Louis, MO | 0000 |
Aclaris Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 15, 2023
32.74 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,421
Rank
Percentile
Pharmaceuticals
Industry
00 of 928
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 456
Rank
Percentile
Aclaris Therapeutics FAQs
-
When was Aclaris Therapeutics founded?
Aclaris Therapeutics was founded in 2012.
-
Who is the founder of Aclaris Therapeutics?
Neal Walker Ph.D, Stuart Shanler MD, Christopher Powala, and Kamil Ali-Jackson JD are the founders of Aclaris Therapeutics.
-
Who is the CEO of Aclaris Therapeutics?
Neal Walker Ph.D is the CEO of Aclaris Therapeutics.
-
Where is Aclaris Therapeutics headquartered?
Aclaris Therapeutics is headquartered in Wayne, PA.
-
What is the size of Aclaris Therapeutics?
Aclaris Therapeutics has 91 total employees.
-
What industry is Aclaris Therapeutics in?
Aclaris Therapeutics’s primary industry is Biotechnology.
-
Is Aclaris Therapeutics a private or public company?
Aclaris Therapeutics is a Public company.
-
What is Aclaris Therapeutics’s stock symbol?
The ticker symbol for Aclaris Therapeutics is ACRS.
-
What is the current stock price of Aclaris Therapeutics?
As of 17-May-2024 the stock price of Aclaris Therapeutics is $1.19.
-
What is the current market cap of Aclaris Therapeutics?
The current market capitalization of Aclaris Therapeutics is $84.8M.
-
What is Aclaris Therapeutics’s current revenue?
The trailing twelve month revenue for Aclaris Therapeutics is $31.1M.
-
Who are Aclaris Therapeutics’s competitors?
Aquapharm (Scotland ), Azitra, Novartis, Revance Therapeutics, and Biogen are some of the 21 competitors of Aclaris Therapeutics.
-
What is Aclaris Therapeutics’s annual earnings per share (EPS)?
Aclaris Therapeutics’s EPS for 12 months was -$1.09.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
